MPI tests are traditionally performed by SPECT (single photon emission computed tomography); however, Cardiac PET is now considered a more advanced imaging technology and is the preferred first-line image testing practice for MPI. It offers numerous advantages for both patients and physicians while creating a platform for medical breakthroughs in diagnostic and treatment capabilities.

Cardiac PET MPI is performed using a minimal radiation dosage compared to SPECT and offers faster procedure times, with imaging sessions taking as little as 45 minutes to complete. This not only achieves higher safety and health standards for the operating clinic but also makes the experience much easier on the patient. In contrast, SPECT testing can take three or more hours to perform.

PET MPI delivers a superior level of imaging quality, interpretive certainty, significantly lower radiation exposure, and diagnosis of microvascular function at rest and peak stress that is considerably enhanced when compared to SPECT. With PET, image acquisition times are significantly reduced, which offers streamlined health diagnoses and aids physicians in recommending an immediate course of treatment. Accuracy produced by Cardiac PET MPI provides a greater element of prognostic potential, which may help affirm surgical needs, medical treatment, lifestyle, and other changes designed to alleviate cardiovascular risk and prevent future heart attacks.

For physicians, Cardiac PET MPI with CDL Nuclear Technologies opens the door to advanced treatment capabilities with no upfront cost. PET MPI can be performed alongside Coronary Flow Reserve (CFR) to better measure coronary artery resistance and other factors that constitute non-obstructive CAD and identify the biological risks of ischemic heart disease. Cardiac PET MPI features such as noninvasive imaging, minimal radiation exposure, and fast acquisition times ensure patient comfort and safety while achieving the highest accuracy and prognostic power currently available in the field of cardiology.